Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis

Taro Edahiroa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Hiroshi Ureshinoa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, JapanCorrespondence[email protected], [email protected]

https://orcid.org/0000-0002-5034-3699

Ren Chishakia Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Keita Fujinoa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Tatsuji Minoa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Tetsumi Yoshidaa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

Noriyasu Fukushimaa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;b Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu, Japan

Tatsuo Ichinohea Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

show all

"Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis." Leukemia & Lymphoma, 63(14), pp. 3511–3512

Acknowledgement

The authors thank Hiroki Yamaguchi (Nihon university, Japan) for gene mutational analysis.

Informed consent

The patient provided informed consent to publish this case report.

Disclosure statement

The Next Generation Development of Genome and Cellular Therapy Program at RIRBM is cooperatively funded by Repertoire Genesis Inc. and Hiroshima University. TI has received research funding from AbbVie Inc. and Nippon Shinyaku Co.. No other authors declare potential conflicts of interest (COI).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis

Information for

Open access

Opportunities

Help and information

Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis

Acknowledgement

Informed consent

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature